Novo Nordisk Gross Margin 2010-2023 | NVO
Current and historical gross margin for Novo Nordisk (NVO) over the last 10 years. The current gross profit margin for Novo Nordisk as of December 31, 2023 is %.
| Novo Nordisk Gross Margin Historical Data |
| Date |
TTM Revenue |
TTM Gross Profit |
Gross Margin |
| 2023-12-31 |
$33.72B |
$28.53B |
84.60% |
| 2023-09-30 |
$30.85B |
$25.96B |
84.16% |
| 2023-06-30 |
$28.44B |
$24.00B |
84.37% |
| 2023-03-31 |
$26.41B |
$22.24B |
84.23% |
| 2022-12-31 |
$25.06B |
$21.03B |
83.92% |
| 2022-09-30 |
$24.32B |
$20.47B |
84.18% |
| 2022-06-30 |
$23.81B |
$19.97B |
83.89% |
| 2022-03-31 |
$23.26B |
$19.40B |
83.38% |
| 2021-12-31 |
$22.40B |
$18.64B |
83.20% |
| 2021-09-30 |
$21.64B |
$17.94B |
82.91% |
| 2021-06-30 |
$20.85B |
$17.30B |
82.98% |
| 2021-03-31 |
$19.93B |
$16.57B |
83.17% |
| 2020-12-31 |
$19.45B |
$16.24B |
83.51% |
| 2020-09-30 |
$19.09B |
$15.98B |
83.69% |
| 2020-06-30 |
$18.74B |
$15.68B |
83.67% |
| 2020-03-31 |
$18.84B |
$15.75B |
83.62% |
| 2019-12-31 |
$18.29B |
$15.28B |
83.54% |
| 2019-09-30 |
$17.43B |
$14.61B |
83.81% |
| 2019-06-30 |
$17.25B |
$14.49B |
84.03% |
| 2019-03-31 |
$17.11B |
$14.39B |
84.10% |
| 2018-12-31 |
$17.10B |
$14.41B |
84.24% |
| 2018-09-30 |
$17.61B |
$14.79B |
83.98% |
| 2018-06-30 |
$17.49B |
$14.68B |
83.95% |
| 2018-03-31 |
$17.33B |
$14.57B |
84.06% |
| 2017-12-31 |
$16.97B |
$14.29B |
84.20% |
| 2017-09-30 |
$16.81B |
$14.15B |
84.21% |
| 2017-06-30 |
$16.73B |
$14.16B |
84.60% |
| 2017-03-31 |
$16.67B |
$14.13B |
84.78% |
| 2016-12-31 |
$16.61B |
$14.06B |
84.62% |
| 2016-09-30 |
$16.56B |
$14.05B |
84.81% |
| 2016-06-30 |
$16.43B |
$13.93B |
84.83% |
| 2016-03-31 |
$16.26B |
$13.82B |
84.94% |
| 2015-12-31 |
$16.06B |
$13.65B |
85.00% |
| 2015-09-30 |
$15.99B |
$13.58B |
84.94% |
| 2015-06-30 |
$15.95B |
$13.51B |
84.68% |
| 2015-03-31 |
$15.92B |
$13.37B |
84.00% |
| 2014-12-31 |
$15.83B |
$13.24B |
83.60% |
| 2014-09-30 |
$15.63B |
$13.09B |
83.73% |
| 2014-06-30 |
$15.31B |
$12.75B |
83.29% |
| 2014-03-31 |
$15.08B |
$12.57B |
83.31% |
| 2013-12-31 |
$14.89B |
$12.37B |
83.08% |
| 2013-09-30 |
$14.58B |
$12.14B |
83.22% |
| 2013-06-30 |
$14.27B |
$11.87B |
83.14% |
| 2013-03-31 |
$13.89B |
$11.53B |
82.97% |
| 2012-12-31 |
$13.48B |
$11.16B |
82.74% |
| 2012-09-30 |
$13.04B |
$10.70B |
82.03% |
| 2012-06-30 |
$12.80B |
$10.42B |
81.44% |
| 2012-03-31 |
$12.52B |
$10.14B |
80.99% |
| 2011-12-31 |
$12.27B |
$9.92B |
80.82% |
| 2011-09-30 |
$12.04B |
$9.68B |
80.44% |
| 2011-06-30 |
$11.85B |
$9.61B |
81.06% |
| 2011-03-31 |
$11.48B |
$9.33B |
81.24% |
| 2010-12-31 |
$11.06B |
$8.97B |
81.17% |
| 2010-09-30 |
$10.66B |
$8.63B |
80.89% |
| 2010-06-30 |
$10.24B |
$8.20B |
80.02% |
| 2010-03-31 |
$9.90B |
$7.88B |
79.64% |
| 2009-12-31 |
$9.67B |
$7.72B |
79.80% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$558.832B |
$33.708B |
|
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
|
